2m 2m 2m 2m 2m 2m 2m
VTV THERAP-A (VTVT)
NASDAQ
$32.97-$0.03 (-0.11%)
Price as of Jun 03, 2026 4:10 PM EDT- $131.4MMarket Cap
- 102.45%1-Year Change
- BiotechnologyIndustry
VTV THERAP-A (VTVT)
$32.97-$0.03 (-0.11%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 0 -100.00% | 1.0M N/A | 0 -100.00% | 2.0M -49.61% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 -100.00% | 1.0M N/A | 0 -100.00% | 2.0M -49.61% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -17.9M +54.69% | -11.5M -15.07% | -13.6M +10.02% | -12.4M -7.26% | |
Depreciation and Amortization Expense | 16,000 -82.02% | 89,000 -1.11% | 90,000 -2.17% | 92,000 +3.37% | |
Total Operating Expenses | 32.8M +30.21% | 25.2M -1.20% | 25.5M +3.84% | 24.6M -4.32% | |
Operating Profit | -32.8M +35.68% | -24.2M -5.18% | -25.5M +13.14% | -22.5M +4.05% | |
Interest Income | 1.9M +19.49% | 1.6M +231.57% | 472,000 +34.09% | 352,000 +35,100.00% | |
Interest Expense | N/A N/A | 0 +100.00% | -13,000 -13.33% | -15,000 +25.00% | |
Interest Income and Expense and Net | 1.9M +19.49% | 1.6M +240.96% | 459,000 +36.20% | 337,000 +3,163.64% | |
Total Nonoperating Income and Expense | -109,000 -168.12% | 160,000 +110.69% | -1.5M -58.60% | -3.6M -247.71% | |
Income before Taxes | -31.1M +37.49% | -22.6M -12.94% | -26.0M +4.39% | -24.9M +41.20% | |
Income Taxes | 0 -100.00% | 100,000 N/A | 0 -100.00% | 200,000 +73.91% | |
Extraordinary Items | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Net Income | -27.0M +46.11% | -18.5M -8.83% | -20.3M +5.67% | -19.2M +47.56% | |
Net Income from Continuing Operations Applicable to Common | -27.0M +46.11% | -18.5M -8.83% | -20.3M +5.67% | -19.2M +47.56% | |
Basic EPS and Net Income | -3.20 0.00% | -3.20 -67.04% | -9.71 +3,634.62% | -0.26 +23.81% | |
Diluted EPS and Net Income | -3.20 0.00% | -3.20 -67.04% | -9.71 +3,634.62% | -0.26 +23.81% | |
Basic Weighted Average Shares | 8.4M +45.96% | 5.8M +38.40% | 4.2M -97.22% | 149.8M +23.29% | |
Diluted Weighted Average Shares | 8.4M +45.96% | 5.8M +38.40% | 4.2M -97.22% | 149.8M +23.29% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 88.9M +142.02% | 36.7M +289.01% | 9.4M -22.10% | 12.1M -9.61% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 88.9M +142.02% | 36.7M +289.01% | 9.4M -22.10% | 12.1M -9.61% | |
Total Current Assets | 89.9M +135.86% | 38.1M +257.63% | 10.7M -60.67% | 27.1M +73.45% | |
Accumulated Depreciation | N/A N/A | 508,000 +4.31% | 487,000 +22.67% | 397,000 +30.16% | |
Property and Plant and Equipment and Net | N/A N/A | 28,000 -76.07% | 117,000 -43.48% | 207,000 -25.54% | |
Total Long-Term Assets | 6,000 -78.57% | 28,000 -76.07% | 117,000 -43.48% | 207,000 -25.54% | |
Total Assets | 89.9M +134.93% | 38.3M +247.30% | 11.0M -66.85% | 33.2M +30.48% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | 0 -100.00% | 191,000 -14.73% | 224,000 -12.50% | |
Total Current Liabilities | 6.6M +27.81% | 5.2M -51.07% | 10.6M +37.77% | 7.7M -9.30% | |
Total Long-Term Debt | N/A N/A | 0 -100.00% | 191,000 -72.08% | 684,000 -45.80% | |
Total Long-Term Liabilities | 18.7M 0.00% | 18.7M -0.90% | 18.8M -0.89% | 19.0M +37,914.00% | |
Total Liabilities | 25.5M +6.25% | 24.0M -18.95% | 29.6M +7.91% | 27.4M +167.26% | |
Retained Earnings | -326.7M +9.00% | -299.7M +6.65% | -281.0M +5.84% | -265.5M +6.71% | |
Total Stockholders Equity | 64.4M +428.22% | 12.2M +149.43% | -24.7M +129.80% | -10.7M +10.27% | |
Total Shares Outstanding | 2.6M +25.29% | 2.1M -60.84% | 5.3M -97.45% | 209.2M +16.15% | |
Cash Flow | |||||
Cash from Operating Activities | -25.3M -0.21% | -25.3M +32.63% | -19.1M +19.09% | -16.0M -17.02% | |
Capital Expenditures | N/A N/A | 0 N/A | 0 -100.00% | 21,000 -70.00% | |
Cash from Investing Activities | 0 N/A | 0 -100.00% | 4.4M +21,071.43% | -21,000 -108.68% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 77.4M +47.21% | 52.6M +338.50% | 12.0M -18.69% | 14.8M -45.31% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | -2,377.58% N/A | N/A N/A | -1,116.95% +106.51% | |
Return on Assets | -42.09% -43.82% | -74.92% -18.13% | -91.51% +40.18% | -65.28% +1.19% | |
Return on Equity | -70.40% -123.79% | 295.84% +158.73% | 114.34% -38.90% | 187.15% +547.33% | |
Revenue Growth | -100.00% N/A | N/A N/A | -100.00% +101.56% | -49.61% +32.10% | |
Current Ratio | 13.54 +84.54% | 7.34 +630.88% | 1.00 -71.45% | 3.52 +91.22% | |
Cash Ratio | 13.39 +89.36% | 7.07 +695.05% | 0.89 -43.46% | 1.57 -0.34% | |
Debt-to-Equity Ratio | N/A N/A | 0.00 +100.00% | -0.02 -81.66% | -0.08 -45.80% | |
Debt-to-Assets Ratio | N/A N/A | 0.00 -100.00% | 0.03 +27.11% | 0.03 -54.19% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow